Patient preference for infusion systems
Part of Immune system & allergy clinical trials.
This study wants to learn which kind of infusion system people prefer when they get their immunoglobulin therapy at home. If you have been using an electronic pump for at least 3 months, your experience can help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a condition like primary immunodeficiency, secondary immunodeficiency, or chronic inflammatory demyelinating polyneuropathy (CIDP).
- You are currently receiving immunoglobulin replacement therapy (IgRT).
- You or your caregiver have been using an electronic subcutaneous immunoglobulin (SCIG) infusion system for at least 3 months.
- You are not taking part in any other clinical study right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
This study examines how well immunoglobulin replacement therapy works in people with primary antibody immunodeficiency—a rare condition where the body cannot make enough antibodies to fight infections. Researchers will also study immune system changes to understand treatment response better.
This study looks at what patients with ITP prefer in their treatments. It may help doctors understand which treatment options matter most to patients like you.
This trial tests a new intravenous immunoglobulin (IVIG) treatment for patients with primary immunodeficiency diseases, such as common variable immune deficiency (CVID) or X-linked agammaglobulinemia (XLA). It aims to see if this medicine is safe and works well to prevent infections.
Hear when a new Primary Immunodeficiencies (PID) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.